Karyopharm Therapeutics (KPTI) Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in PFS in Patients with Multiple Myeloma
Go back to Karyopharm Therapeutics (KPTI) Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in PFS in Patients with Multiple Myeloma| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 1.70 -0.02 (1.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.72 | 52 Week High | $19.41 | |||
| Open | $1.72 | 52 Week Low | $4.83 | |||
| Day High | $1.75 | P/E | N/A | |||
| Day Low | $1.69 | EPS | $-2.74 | |||
| Volume | 137,728 | |||||
